Shanghai-based clinical stage innovative drug maker Elpiscience Biopharma has received a corpus of $105 million in a Series C round of financing led by the Greater Bay Area Homeland Development Fund — a state-backed, $14.8 billion industry fund launched in 2018 to support high-tech industries in the Guangdong-Hong Kong-Macao Greater Bay Area.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
